Navigation Links
TransPharma Medical Announces Positive Results of Phase I Clinical,Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis,Treatment

ng the highest reported bioavailability of alternative drug delivery routes to subcutaneous administration.

"We are very excited by the results of our phase I studies. The promising findings are further validation that the ViaDerm-hPTH (1-34) product can provide a viable alternative administration route for hPTH (1-34) for women suffering from osteoporosis, which would alleviate the pain and inconvenience associated with their current treatment, thereby increasing compliance," said Dr. Daphna Heffetz, CEO of TransPharma Medical Ltd. "Strongly encouraged by the results of our series of phase I studies, which included a total of 66 post-menopausal healthy women volunteers, we plan to initiate a phase II study of the ViaDerm-hPTH (1-34) product, bringing this potential product to an advanced clinical stage before seeking a partner to take it to market," Dr. Heffetz added.

About Osteoporosis

hPTH (1-34) is currently the only osteoporosis drug to possess anabolic properties. According to the National Osteoporosis Foundation, approximately 10 million people in the US currently suffer from osteoporosis and another 34 million are estimated to have low bone mass, placing them at increased risk for the disease. Over the next five years, the number of people suffering from osteoporosis is expected to reach 52 million, creating a $10.4 billion market by 2011.

About the ViaDerm System

TransPharma's ViaDerm drug delivery system incorporates a handheld electronic control unit combined with a drug patch. The system provides a cost-effective, easy-to-use, self-administered solution that enables the safe, reproducible and accurate delivery of a wide variety of product candidates, including hydrophilic small molecules, peptides and proteins.

About TransPharma Medical

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietar
'"/>




Page: 1 2 3

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
7. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
8. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester
9. Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
10. Limiting Eligibility for Medical Studies Can Omit Women, African-Americans, Stanford Study Finds
11. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
Post Your Comments:
Breaking Medicine Technology:Particle Sciences and IES Engineers Cooperate on High Potency Compound Handling Capabilities 2Particle Sciences and IES Engineers Cooperate on High Potency Compound Handling Capabilities 3Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 2Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 3BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in China's National Insurance Catalog 2BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in China's National Insurance Catalog 3Sodexo Offers Landmark Program to Promote Employee Health and Worklife Balance 52404 1Sodexo Offers Landmark Program to Promote Employee Health and Worklife Balance 52404 2SOWSIAs Inpatient EHR Solution Gets 08 CCHIT Certification 52400 1SOWSIAs Inpatient EHR Solution Gets 08 CCHIT Certification 52400 2SOWSIAs Inpatient EHR Solution Gets 08 CCHIT Certification 52400 3Young Adults Unaware of Threat of Infectious Disease and the Availability of Preventive Vaccines 52396 1Young Adults Unaware of Threat of Infectious Disease and the Availability of Preventive Vaccines 52396 2Young Adults Unaware of Threat of Infectious Disease and the Availability of Preventive Vaccines 52396 3Young Adults Unaware of Threat of Infectious Disease and the Availability of Preventive Vaccines 52396 4Young Adults Unaware of Threat of Infectious Disease and the Availability of Preventive Vaccines 52396 5Young Adults Unaware of Threat of Infectious Disease and the Availability of Preventive Vaccines 52396 6